Stocktoria
Entera Bio Ltd. ENTX
Entera Bio Ltd. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $42,000 | $181,000 | $0 | $134,000 | $571,000 | $365,000 |
| Gross profit | $0 | $9,000 | $0 | $33,000 | $198,000 | $65,000 |
| R&D expense | $6.0M | $4.5M | $4.5M | $5.8M | $6.8M | $6.4M |
| SG&A expense | $398,000 | $340,000 | — | — | — | — |
| Operating income | -$11.5M | -$9.6M | -$8.9M | -$13.0M | -$12.2M | -$11.2M |
| Income tax | $0 | $14,000 | $29,000 | $137,000 | -$59,000 | $20,000 |
| Net income | -$11.4M | -$9.5M | -$8.9M | -$13.1M | -$12.2M | -$11.2M |
| EPS (diluted) | $0.25 | $0.25 | $0.31 | $0.45 | $0.47 | — |
| Operating cash flow | -$7.4M | -$6.8M | -$7.3M | -$12.5M | -$9.1M | -$10.6M |
| Free cash flow | -$7.5M | -$6.8M | -$7.3M | -$12.5M | -$9.1M | -$10.6M |
| Cash & equivalents | $7.1M | $8.7M | $11.0M | $12.3M | $24.9M | $8.6M |
| Total assets | $16.0M | $9.4M | $11.8M | $13.1M | $26.0M | $9.7M |
| Total liabilities | $2.9M | $1.3M | $1.4M | $1.4M | $3.4M | $2.2M |
| Shareholders' equity | $13.1M | $8.1M | $10.4M | $11.8M | $22.6M | $7.5M |
Growth · year-over-year · Revenue CAGR -35.1%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | -76.8% | — | -100.0% | -76.5% | +56.4% | — |
| EPS growth | +0.0% | -19.4% | -31.1% | -4.3% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.